Forward Therapeutics
PrivateLast Round
Series A
Oct 31, 2023
Total Funding Raised
$66M
Company Overview
Forward Therapeutics is a biotechnology company that develops oral small-molecule therapies for the treatment of inflammation-driven diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Forward Therapeutics Comparables
Compare Forward Therapeutics with similar companies based on industry and business-model similarity.
Forward Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Oct 31, 2023 | ||||
| Seed | May 1, 2022 |
Forward Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| RA Capital Management | Series A |
| OrbiMed | Series A |
| BVF Partners L.P. | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 18, 2026
Monthly visitors increased 42% MoM, from 757 to 1.1K.
- Nov 8, 2023
$50M round with OrbiMed and RA Capital Management
Forward Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Forward Therapeutics's valuation, stock price, and market status.